September 2007 Update on EORTC Guidelines and Anemia Management with Erythropoiesis-Stimulating Agents
about
The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agentsRole of iron supplementation to erythropoiesis stimulating agents in the management of chemotherapy-induced anemia in cancer patientsHemoglobin level at initiation of darbepoetin alfa: impact on need for transfusion and associated costs in chemotherapy-induced anemia treatment in EuropePrevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. ironEffects of erythropoiesis-stimulating agents on fatigue- and anaemia-related symptoms in cancer patients: systematic review and meta-analyses of published and unpublished dataAntianemic Treatment of Cancer Patients in German Routine Practice: Data from a Prospective Cohort Study-The Tumor Anemia Registry.Final results of a phase I/II pilot study of capecitabine with or without vinorelbine after sequential dose-dense epirubicin and paclitaxel in high-risk early breast cancerA European patient record study on diagnosis and treatment of chemotherapy-induced anaemia.Prognostic significance of erythropoietin in pancreatic adenocarcinomaDetection, evaluation, and management of preoperative anaemia in the elective orthopaedic surgical patient: NATA guidelines.Cancer and renal insufficiency results of the BIRMA study.When is high-dose intravenous iron repletion needed? Assessing new treatment options.Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemiaPredictors and patterns of red blood cell transfusion use among newly diagnosed cancer patients with chemotherapy-associated anemia in Western Denmark (1998-2003)Post-diagnosis hemoglobin change associates with overall survival of multiple malignancies - results from a 14-year hospital-based cohort of lung, breast, colorectal, and liver cancers.Comparative cost efficiency across the European G5 countries of originators and a biosimilar erythropoiesis-stimulating agent to manage chemotherapy-induced anemia in patients with cancerThe risk for anemia with targeted therapies for solid tumorsComparative Effectiveness of Biosimilar, Reference Product and Other Erythropoiesis-Stimulating Agents (ESAs) Still Covered by Patent in Chronic Kidney Disease and Cancer Patients: An Italian Population-Based StudySupportive therapy in medical therapy of head and neck tumors.The role of intravenous iron in the treatment of anemia in cancer patientsOnco-nephrology: an appraisal of the cancer and chronic kidney disease links.Prevalence and management of anaemia in patients with non-myeloid cancer undergoing systemic therapy: a Spanish survey.Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trialBudget impact analysis on erythropoiesis-stimulating agents use for the management of chemotherapy-induced anaemia in Greece.Anemia prevalence and treatment practice in patients with non-myeloid tumors receiving chemotherapy.Combination with intravenous iron supplementation or doubling erythropoietin dose for patients with chemotherapy-induced anaemia inadequately responsive to initial erythropoietin treatment alone: study protocol for a randomised controlled trial.Iron deficiency in cancer patients.Pharmacoutilization of epoetins in naïve patients with hematological malignancies in an unselected Italian population under clinical practice setting: a comparative analysis between originator and biosimilars.Epoetin-beta treatment in patients with cancer chemotherapy-induced anaemia: the impact of initial haemoglobin and target haemoglobin levels on survival, tumour progression and thromboembolic events.Erythropoiesis-stimulating agents in patients with cancer: update on safety issues.Efficacy and safety of darbepoetin alfa initiated at hemoglobin ≤10 g/dL in patients with stage IV cancer and chemotherapy-induced anemia.Perioperative anemia management in colorectal cancer patients: a pragmatic approach.Erythropoietic stimulating agents.Comparative effectiveness and safety of erythropoiesis-stimulating agents (biosimilars vs originators) in clinical practice: a population-based cohort study in Italy.Erythropoiesis-stimulating agents in cancer patients: reflections on safety.Colony stimulating factors (CSF) biosimilars. Progress?Prevalence and significance of anaemia in patients receiving long-course neoadjuvant chemoradiotherapy for rectal carcinoma.Darbepoetin alfa in the treatment of anemia in cancer patients undergoing chemotherapy.Pharmacovigilance in practice: erythropoiesis-stimulating agents.Experimental and investigational therapies for chemotherapy-induced anemia.
P2860
Q24186166-03D5C706-2082-4A97-87CD-72F011BCB014Q24203798-602B430A-AA4B-4215-A92A-39F9C4BB9470Q26865984-DE0840C6-394D-4654-8F13-3D12CF4A95C3Q27004170-721B582A-7A64-4388-A7AF-AA2444174D6BQ30803363-AF48C5D6-155D-4538-9550-3CEBB8F08C23Q31056773-A3276ED0-E855-46CF-AD5F-B3B1168F2F6FQ33659628-6BFFC297-FCD1-4EC6-931F-85E22610387AQ33848929-935670CE-4E0D-4452-9CD8-C6215013904DQ33988762-35EA2448-B96B-434B-BD4A-994B33A01779Q34399172-D9BC4957-AEB3-42EB-9BE6-25E0FE5A7511Q34433767-9EF55E4E-DDC7-4D9F-A3B9-12245074F889Q34574079-9D500F81-7FC2-4654-907F-3DF1ED2D2764Q34662889-17CAD078-1626-4642-A544-8D300ED80BFFQ34769270-2BF18EC6-7C23-4FE1-BA13-873AB4539A6BQ34810071-551499F3-C1F5-4E0A-BBCF-062DE335EBB2Q35949310-D7706DCE-D898-40B8-8F6C-84E23DA8EA35Q35989994-31819136-B719-4221-9374-033AF2BFF558Q36019803-7DB41A0F-579A-4461-AD64-6A020A54674AQ36529853-35926A95-791E-4DC0-A814-313DB5A8CA35Q36612686-395A57E2-7F3D-4A88-A800-5EE71C942D38Q36801561-77037C7C-B1B5-4088-A111-C62D4EC091EFQ36875147-B969860C-24C7-4424-98A9-88EF2F42DA11Q37021210-EF8D88F4-6E74-465B-9F70-59224EE96CD9Q37028832-E27448D9-CCBB-4D13-8549-455DEDAB593DQ37084851-9D078308-7E55-4DAD-A2F0-A0BFE6883BEDQ37355996-794E2248-6628-49DE-A9CF-0DC8B5597A82Q37429231-CF82E255-7870-4EF7-A702-E259E1800086Q37474361-EE5824AD-D81C-475E-8E34-FFF6EDC01D06Q37481924-1BA0ADC2-D941-4D33-9501-8E6A8F76C637Q37564558-4A6B3DEE-D791-4231-9B7E-2884669560B7Q37577927-3F751D12-8D71-46FD-8F93-2E494E0F92F7Q37602724-BA28942E-C09D-4B8D-A901-EB49DBECE3E5Q37693160-C6CF70C3-C66C-4D35-922E-155C10DD8477Q37704338-FEAE9DF2-F0FB-4563-862B-D7AEF7D32EA7Q37960528-DA482093-60C0-4FC3-8126-0666694CCC96Q37976333-FDC3B2AA-492A-4B7E-A66C-0078AE48CAD6Q38014143-A5381CC3-CAEC-4D0E-A171-0189F331DBCEQ38056750-FF2DB1E3-F264-4367-BEFC-104FA20C4C9BQ38217083-C519953B-AB19-40DD-A9C2-DCDA07FE2A5FQ38584639-71ACAE14-91C6-433E-A428-F081CFCC4414
P2860
September 2007 Update on EORTC Guidelines and Anemia Management with Erythropoiesis-Stimulating Agents
description
2008 nî lūn-bûn
@nan
2008 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
name
September 2007 Update on EORTC ...... thropoiesis-Stimulating Agents
@ast
September 2007 Update on EORTC ...... thropoiesis-Stimulating Agents
@en
September 2007 Update on EORTC ...... thropoiesis-Stimulating Agents
@en-gb
September 2007 Update on EORTC ...... thropoiesis-Stimulating Agents
@nl
type
label
September 2007 Update on EORTC ...... thropoiesis-Stimulating Agents
@ast
September 2007 Update on EORTC ...... thropoiesis-Stimulating Agents
@en
September 2007 Update on EORTC ...... thropoiesis-Stimulating Agents
@en-gb
September 2007 Update on EORTC ...... thropoiesis-Stimulating Agents
@nl
altLabel
September 2007 update on EORTC ...... thropoiesis-stimulating agents
@en
prefLabel
September 2007 Update on EORTC ...... thropoiesis-Stimulating Agents
@ast
September 2007 Update on EORTC ...... thropoiesis-Stimulating Agents
@en
September 2007 Update on EORTC ...... thropoiesis-Stimulating Agents
@en-gb
September 2007 Update on EORTC ...... thropoiesis-Stimulating Agents
@nl
P3181
P1433
P1476
September 2007 Update on EORTC ...... thropoiesis-Stimulating Agents
@en
P2093
P3181
P356
10.1634/THEONCOLOGIST.13-S3-33
P407
P433
Supplement 3
P577
2008-05-01T00:00:00Z